Lutein Supplementation May Improve Outcomes in Early AMD

Meta-analysis found statistically significant improvements, with clearest benefits in early-stage disease

By
Andrea Surnit
May 5, 2026
3 min

Conexiant

Overview

Lutein supplementation is associated with improved macular pigment optical density and best-corrected visual acuity in patients with early-stage age-related macular degeneration (AMD). This systematic review and meta-analysis of nine trials suggests significant benefits from lutein, particularly in early-stage disease.

Background

Age-related macular degeneration (AMD) is a leading cause of vision loss in older adults, making effective management crucial. Lutein, a carotenoid found in green leafy vegetables, has been studied for its potential protective effects on retinal health. Understanding the impact of lutein supplementation on AMD outcomes can guide clinical practice and patient management.

Data Highlights

Outcome	Effect Size	Significance
Macular Pigment Optical Density (MPOD)	Moderate-to-large	Statistically significant
Best-Corrected Visual Acuity (BCVA)	Moderate-to-large	Statistically significant in early-stage AMD

Key Findings

Lutein supplementation improved MPOD and BCVA compared to placebo.
Significant benefits were observed in patients with early-stage AMD, but not in late-stage or mixed-stage populations.
Lutein monotherapy showed improvements in both MPOD and BCVA, while combination formulations improved MPOD but not BCVA.
Longer supplementation duration and greater cumulative lutein exposure correlated with larger changes in MPOD and BCVA.
Secondary analyses indicated improvements in contrast sensitivity and increased serum lutein concentrations.

Clinical Implications

Discuss potential risks or considerations for patients regarding lutein supplementation.

Conclusion

Lutein-based supplementation offers measurable benefits for patients with early-stage AMD, emphasizing the importance of tailored nutritional interventions in managing this chronic condition.